What constitutes meaningful improvement in myelodysplastic syndromes?

References

• Nimer SD. Myelodysplastic syndromes. Blood. 2008;111(10):4841–4851.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15.
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach T, Kern W, et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007;92(6):744–752.
   PubMedGoogle Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–2506.
   PubMed Web of Science ®Google Scholar
• del Rey M, O'Hagan K, Dellett M, et al. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. Leukemia. 2013;27(3):610–618.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114(16):3448–3458.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671–3674.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Fenaux P, Adès L, et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood. 2019;133(10):1020–1030.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognosis scoring system for myelodysplastic syndromes. In American society of hematology annual meeting 2021. Atlanta, Georgia, USA; 2021.
   Google Scholar
• Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376–3382.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012 Sep 20;30(27):3376–82. doi: 10.1200/JCO.2011.40.7379. Epub 2012 Aug 6. PMID: 22869879; PMCID: PMC3438234, https://pubmed.ncbi.nlm.nih.gov/22869879.
   PubMed Web of Science ®Google Scholar
• Stauder R, Yu G, Koinig KA, et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018;32(6):1380–1392.
   PubMed Web of Science ®Google Scholar
• Abel GA, Efficace F, Buckstein RJ, et al. Prospective international validation of the quality of life in myelodysplasia scale (QUALMS). Haematologica. 2016;101(6):781–788.
   PubMed Web of Science ®Google Scholar
• Getta BM, Kishtagari A, Hilden P, et al. Allogeneic hematopoietic stem cell transplantation is underutilized in older patients with myelodysplastic syndromes. Biol Blood Marrow Transplantat. 2017;23(7):1078–1086.
   PubMedGoogle Scholar
• Denny SD, Kuchibhatla MN, Cohen HJ. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med. 2006;119(4):327–334.
   PubMed Web of Science ®Google Scholar
• Culleton BF, Manns BJ, Zhang J, et al. Impact of anemia on hospitalization and mortality in older adults. Blood. 2006;107(10):3841–3846.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic scoring system (WPSS). Haematologica. 2011;96(10):1433–1440.
   PubMed Web of Science ®Google Scholar
• Buckstein R, Alibhai S, Lam A, et al. Transfusion dependence and low hemoglobin have the greatest impact on quality of life (QOL) in MDS patients – a tertiary care cross sectional and longitudinal study. Blood. 2009;114(22):2500–2500.
   Google Scholar
• Szende A, Schaefer C, Goss TF, et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes. 2009;7(1):81.
   PubMedGoogle Scholar
• Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542–1551.
   PubMedGoogle Scholar
• Tanasijevic AM, Revette A, Klepin HD, et al. Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leuk Lymphoma. 2020;61(12):2900–2904.
   PubMed Web of Science ®Google Scholar
• Administration, U. S. F. a. D. FDA approves luspatercept-aamt for anemia in adults with MDS. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-adults-mds.
   Google Scholar
• Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140–151.
   PubMed Web of Science ®Google Scholar
• Hutzschenreuter F, Monsef I, Kreuzer KA, et al. Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes. Cochrane Database Syst Rev. 2016;2:CD009310.
   PubMedGoogle Scholar
• Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120(12):1838–1846.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Sekeres MA, Kantarjian H, et al. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial. Leukemia. 2014;28(12):2418–2421.
   PubMedGoogle Scholar
• Oliva EN, Platzbecker U, Garcia-Manero G, et al. Health-related quality of life outcomes in patients with myelodysplastic syndromes with ring sideroblasts treated with luspatercept in the medalist study. Blood. 2020;136(Supplement 1):10–12.
   Web of Science ®Google Scholar
• Scarfò L, Karamanidou C, Doubek M, et al. MyPal ADULT study protocol: a randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies. BMJ Open. 2021;11(11):e050256.
   PubMedGoogle Scholar
• Abel GA, Klepin HD, Magnavita ES, et al. Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes. Transfusion. 2021;61(10):2830–2836.
   PubMedGoogle Scholar
• Brunner AM, Gavralidis A, Al Ali N, et al. Evaluating complete remission with incomplete hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS). Blood. 2021;138(Supplement 1):1522–1522.
   Google Scholar
• Sekeres MA, Othus M, List AF, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in Higher-Risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North american intergroup study SWOG S1117. J Clin Oncol. 2017;35(24):2745–2753.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and azacitidine in TP53-Mutant myelodysplastic syndromes. J Clin Oncol. 2021;39(14):1584–1594.
   PubMed Web of Science ®Google Scholar
• Cluzeau T, Sebert M, Rahmé R, et al. Eprenetapopt plus azacitidine in TP53-Mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol. 2021;39(14):1575–1583.
   PubMed Web of Science ®Google Scholar
• Therapeutics A. Aprea therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS). https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-results-primary-endpoint-phase-3.
   Google Scholar
• Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012;120(25):4945–4951.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Montalban-Bravo G, Berdeja JG, et al. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer. 2017;123(6):994–1002.
   PubMed Web of Science ®Google Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US leukemia intergroup trial E1905. J Clin Oncol. 2014;32(12):1242–1248.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Watts J, Radinoff A, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021;35(7):2119–2124.
   PubMed Web of Science ®Google Scholar
• Sebert M, Cluzeau T, Beyne Rauzy O, et al. Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the idiome phase 2 study by the GFM group. Blood. 2021;138(Supplement 1):62–62.
   Google Scholar